T. Rowe Price Associates
CATX icon

T. Rowe Price Associates’s Perspective Therapeutics CATX Stock Holding History

T. Rowe Price Associates’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Buy
85,930
+43,648
+103% +$165K ﹤0.01% 2857
2026
Q1 		$177K Buy
42,282
+12,513
+42% +$52.9K ﹤0.01% 2876
2025
Q4 		$82K Hold
29,769
– – ﹤0.01% 2969
2025
Q3 		$103K Buy
29,769
+978
+3% +$3.56K ﹤0.01% 2915
2025
Q2 		$100K Buy
28,791
+5,351
+23% +$14.1K ﹤0.01% 2892
2025
Q1 		$50K Buy
23,440
+3,748
+19% +$11.2K ﹤0.01% 2933
2024
Q4 		$63K Buy
19,692
+1,784
+10% +$14.6K ﹤0.01% 2901
2024
Q3 		$240K Buy
17,908
+2,889
+19% +$38.4K ﹤0.01% 2574
2024
Q2 		$0 Buy
+15,019
New +$217K ﹤0.01% 2942
2022
Q1 		– Sell
-6,150
Closed -$24K – 2985
2021
Q4 		$24K Hold
6,150
– – ﹤0.01% 2955
2021
Q3 		$39K Hold
6,150
– – ﹤0.01% 2913
2021
Q2 		$49K Hold
6,150
– – ﹤0.01% 2900
2021
Q1 		$67K Buy
+6,150
New +$92.9K ﹤0.01% 2806

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

T. Rowe Price Associates's CATX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Perspective Therapeutics (CATX) stake by 103% in Q2 2026, buying an estimated $165K and bringing the position to 85,930 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #2857.

T. Rowe Price Associates first reported a position in CATX in Q1 2021 and has held it in 13 quarters since. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • T. Rowe Price Associates held 85,930 shares of Perspective Therapeutics worth $294K as of Q2 2026.
  • T. Rowe Price Associates bought 43,648 Perspective Therapeutics shares in Q2 2026, an estimated $165K.
  • Perspective Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2857 holding.
  • T. Rowe Price Associates first reported a position in Perspective Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.